Patents Assigned to S.L.A. Pharma AG
-
Patent number: 11013709Abstract: The present invention relates to a method of administering an effective dose of highly purified eicosapentaenoic acid as free-fatty acid (EPA-FFA) to reduce fecal calprotectin levels and reduce the risk of clinical relapse in UC patients. The eicosapentaenoic acid, in the free fatty acid (EPA-FFA) form, has a purity of at least 95%, and more preferably at least 99%.Type: GrantFiled: August 8, 2019Date of Patent: May 25, 2021Assignee: S.L.A. PHARMA AGInventor: Justin Slagel
-
Patent number: 10881640Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.Type: GrantFiled: August 11, 2016Date of Patent: January 5, 2021Assignee: S.L.A. PHARMA AGInventors: David Nigel Armstrong, Justin Slagel
-
Patent number: 10653671Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.Type: GrantFiled: March 15, 2013Date of Patent: May 19, 2020Assignee: S.L.A. PHARMA, AGInventors: David Nigel Armstrong, Justin Slagel
-
Patent number: 8906903Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.Type: GrantFiled: November 26, 2012Date of Patent: December 9, 2014Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillps
-
Publication number: 20130217741Abstract: A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Applicant: S.L.A. PHARMA AGInventor: S.L.A. PHARMA AG
-
Patent number: 8318721Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.Type: GrantFiled: July 8, 2011Date of Patent: November 27, 2012Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillips
-
Patent number: 8048875Abstract: Bethanechol, diltiazem, or a combination thereof is administered locally to the anus for the treatment of benign anal disorders, in particular anal fissures and hemorrhoids. The agents induce a reduction in the mean and resting pressure, thereby assisting in the healing of the anal fissures and hemorrhoids.Type: GrantFiled: February 23, 1997Date of Patent: November 1, 2011Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillips
-
Patent number: 7928146Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an ?adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2?, dopamine, morphine, ?-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomisis.Type: GrantFiled: March 18, 2003Date of Patent: April 19, 2011Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillips
-
Patent number: 7781444Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an ? adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2?, dopamine, morphine, ?-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomosis.Type: GrantFiled: October 31, 2007Date of Patent: August 24, 2010Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K.S. Phillips
-
Publication number: 20060240123Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.Type: ApplicationFiled: August 22, 2003Publication date: October 26, 2006Applicant: S.L.A. PHARMA AGInventor: David Armstrong
-
Publication number: 20040028752Abstract: A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.Type: ApplicationFiled: August 8, 2002Publication date: February 12, 2004Applicant: S.L.A. Pharma AG.Inventors: Michael A. Kamm, Robin K.S. Phillips
-
Publication number: 20030216420Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an a adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2&agr;, dopamine, morphine, &bgr;-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomisis.Type: ApplicationFiled: March 18, 2003Publication date: November 20, 2003Applicant: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K.S. Phillips
-
Patent number: 6635678Abstract: Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an a adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2&agr;, dopamine, morphine, &bgr;-blockers, and 5-Hydroxytryptamine. The patients who benefit most from the invention are those who have a normal or low maximum anal resting pressure and a structurally intact internal anal sphincter muscle, and patients who have had major bowel resection and reanastomisis.Type: GrantFiled: August 24, 1999Date of Patent: October 21, 2003Assignee: S.L.A. Pharma AGInventors: Michael A. Kamm, Robin K. S. Phillips